Cltrn Antibody

What is Collectrin (CLTRN) and why are antibodies against it important in renal research?

Collectrin (CLTRN) is a 222-amino acid transmembrane glycoprotein that serves as a homolog of angiotensin-converting enzyme 2 (ACE2), though it notably lacks the active dipeptidyl carboxypeptidase catalytic domains that characterize ACE2 . CLTRN functions primarily as a chaperone protein for neutral amino acid transporters in the apical membranes of proximal tubular cells (PTCs) . Antibodies against CLTRN are critical for investigating its expression patterns, subcellular localization, and functional interactions with amino acid transporters in kidney tissue. These antibodies enable researchers to track CLTRN distribution in experimental models of diabetes and obesity, providing insights into how CLTRN mediates amino acid influx into proximal tubular cells and potentially contributes to kidney disease pathology.

Where is CLTRN primarily expressed and how can antibodies help identify its distribution?

CLTRN exhibits tissue-specific expression with high concentrations in the apical brush border of proximal tubular cells, collecting duct cells, and pancreatic β cells . Immunohistochemical studies using validated CLTRN antibodies reveal that the protein localizes predominantly to the apical membrane of proximal tubular epithelial cells, where it facilitates the trafficking of amino acid transporters. When designing studies to map CLTRN distribution, researchers should employ dual immunofluorescence staining with markers for specific nephron segments to accurately determine the expression pattern along the nephron. Electron microscopy immunogold labeling with CLTRN antibodies can provide subcellular resolution of CLTRN localization at the brush border membrane.

What is the functional relationship between CLTRN and amino acid transporters?

CLTRN serves as an essential chaperone for multiple amino acid transporters, particularly those responsible for neutral amino acid uptake in proximal tubular cells . Research with CLTRN knockout models demonstrates that CLTRN deficiency leads to significant downregulation of key transporters including SLC6A19 (B0AT1) for neutral/aromatic amino acids, SLC6A18 (B0AT3) for glycine and glutamine, and SLC6A20 (IMINO) for proline . The association between CLTRN and these transporters is critical for their proper trafficking to and stable expression at the apical membrane. Without CLTRN's chaperone function, these transporters fail to reach their functional location, resulting in generalized aminoaciduria. Antibodies against CLTRN can be used in co-immunoprecipitation experiments to identify the specific protein interactions and in trafficking studies to monitor transport protein movement in response to metabolic stimuli.

How do researchers distinguish between CLTRN and other ACE2 homologs when using antibodies?

Distinguishing CLTRN from other ACE2 homologs requires antibodies with carefully validated specificity profiles. Although CLTRN shares the C-terminal domain with ACE2, it lacks the N-terminal catalytic domains that define ACE2 functionality . When selecting or generating antibodies against CLTRN, researchers should target epitopes within unique regions that don't share homology with ACE2. Validation protocols should include Western blotting against both CLTRN and ACE2 recombinant proteins, as well as testing in tissue from CLTRN knockout mice as a negative control. Cross-reactivity testing is essential, as is preabsorption with the immunizing peptide to confirm specificity. Additionally, comparing immunostaining patterns with established expression profiles can help verify that the antibody is indeed detecting CLTRN rather than other homologous proteins.

How does CLTRN deficiency impact diabetic kidney disease progression in experimental models?

CLTRN deficiency demonstrates unexpected protective effects against diabetic kidney disease progression in experimental models. In streptozotocin and high-fat diet (STZ-HFD) treated mice, Cltrn knockout (Cltrn−/y) animals showed significantly reduced urinary albumin creatinine ratio compared to their wild-type counterparts at 20 weeks of age . Additionally, the kidney injury molecule-1/creatinine ratio was significantly lower in STZ-HFD-Cltrn−/y mice (8.59±4.47 pg/mg) compared to STZ-HFD-Cltrn+/y mice (18.3±5.19 pg/mg) . This protective effect appears to be mediated through reduced amino acid influx into proximal tubular cells, which subsequently modulates key intracellular signaling pathways involved in diabetes-related kidney injury. Researchers using CLTRN antibodies can track changes in CLTRN expression during disease progression and correlate these with histopathological changes and biochemical markers of renal function.

What mechanisms underlie the protective effects of CLTRN knockout in diabetes models?

The protective effects of CLTRN deficiency in diabetic kidney disease models involve several interconnected molecular mechanisms:

These mechanisms collectively contribute to the amelioration of proximal tubular cell injury in diabetic conditions. CLTRN antibody-based studies can help elucidate these pathways by enabling the visualization of CLTRN interaction with transporters and downstream signaling molecules under various experimental conditions .

What is the relationship between CLTRN, mTOR pathway, and transcription factor EB in proximal tubular cells?

CLTRN deficiency establishes a critical regulatory axis involving amino acid sensing, mTOR activity, and transcription factor EB (TFEB) in proximal tubular cells. In STZ-HFD-treated mice, CLTRN knockout results in reduced phospho-mTOR levels and decreased phosphorylation of TFEB . Normally, mTOR acts as a nutrient sensor that is activated by amino acid influx; when active, it phosphorylates TFEB, keeping this transcription factor in an inactive cytoplasmic state. With reduced amino acid entry in CLTRN-deficient cells, mTOR activity diminishes, allowing unphosphorylated TFEB to translocate to the nucleus where it upregulates genes involved in lysosomal biogenesis and autophagy . This shift enhances cellular recycling processes and protects against the accumulation of damaged proteins and organelles that occurs in diabetic kidney disease. Antibodies against phosphorylated and total forms of both mTOR and TFEB are essential tools for researchers studying this pathway in conjunction with CLTRN expression.

How does amino acid profiling correlate with CLTRN expression in normal and pathological states?

Amino acid profiling reveals distinctive patterns that correlate with CLTRN expression status and pathological conditions. In CLTRN-deficient mice (Cltrn−/y), urinary concentrations of 17 amino acids were significantly elevated compared to wild-type mice (Cltrn+/y) under standard diet conditions . Under diabetic conditions (STZ-HFD treatment), the CLTRN gene deficiency caused significant increases in urinary amino acid concentrations of neutral amino acids including glutamine, histidine, glycine, threonine, valine, tryptophan, phenylalanine, isoleucine, leucine, and proline . This amino acid spillage pattern reflects the specific transporters chaperoned by CLTRN, predominantly those handling neutral amino acids. Researchers can use CLTRN antibodies in combination with amino acid profiling to correlate CLTRN expression levels with transport function in various experimental models and human kidney samples, providing insights into the relationship between transporter activity and disease progression.

What are the optimal techniques for generating and validating CLTRN antibodies for research applications?

Generating highly specific CLTRN antibodies requires careful epitope selection and rigorous validation protocols:

• Epitope Selection: Target unique regions of CLTRN that don't share homology with ACE2, preferably in the N-terminal domain or specific loop regions. Both monoclonal and polyclonal approaches can be effective, though monoclonals typically offer higher specificity.

• Expression Systems: For antigen production, consider using eukaryotic expression systems such as HEK293 cells to ensure proper post-translational modifications of CLTRN.

• Validation Protocol:

  • Western blotting against recombinant CLTRN and tissue lysates from kidney samples

  • Comparative analysis in wild-type versus Cltrn−/y tissue

  • Immunoprecipitation followed by mass spectrometry identification

  • Immunohistochemistry with signal blocking using immunizing peptide

  • Dual labeling with established proximal tubule markers

• Cross-reactivity Testing: Verify absence of reactivity against ACE2 and other related proteins, particularly in assays where specificity is paramount.

These methodical approaches ensure that antibodies used in CLTRN research accurately detect the target protein without introducing artifacts that might confound experimental interpretations.

What experimental models are most suitable for studying CLTRN function using antibody-based techniques?

Several experimental models provide valuable platforms for studying CLTRN function with antibody-based techniques:

When using CLTRN antibodies in these models, researchers should establish appropriate staining protocols specific to each system. For instance, perfusion fixation may be optimal for murine kidney tissue, while different fixation methods might be required for cultured cells or human biopsy material . Comparing CLTRN expression patterns across these different models can provide comprehensive insights into its regulation and function in normal and disease states.

How can researchers effectively incorporate CLTRN antibodies in studies of amino acid transport mechanisms?

To effectively incorporate CLTRN antibodies in amino acid transport studies, researchers should implement multifaceted approaches:

• Co-localization Studies: Use dual immunofluorescence with CLTRN antibodies and antibodies against specific amino acid transporters (SLC6A19, SLC6A18, SLC6A20) to visualize their spatial relationship at the apical membrane.

• Transport Activity Correlation: Combine immunohistochemical quantification of CLTRN expression with functional measurements of amino acid uptake in isolated proximal tubule segments or cultured cells.

• Trafficking Analysis: Employ pulse-chase experiments with surface biotinylation and CLTRN antibodies to track the movement of transporters to and from the plasma membrane under various conditions.

• Protein-Protein Interaction Studies: Use CLTRN antibodies for co-immunoprecipitation followed by Western blotting or mass spectrometry to identify the complete interactome of CLTRN in the context of amino acid transport.

• Proximity Ligation Assays: Apply this technique with CLTRN antibodies and transporter antibodies to verify direct interactions at the molecular level within intact cells.

These methodologies allow researchers to establish mechanistic links between CLTRN expression, transporter localization, and functional amino acid transport activities in various physiological and pathological states .

What controls and standards should be included when performing immunohistochemistry with CLTRN antibodies?

Rigorous controls are essential for reliable immunohistochemistry with CLTRN antibodies:

• Negative Controls:

  • Tissue from Cltrn−/y mice to establish background staining levels

  • Primary antibody omission to detect non-specific secondary antibody binding

  • Isotype controls matched to the CLTRN antibody class and concentration

• Positive Controls:

  • Wild-type kidney tissue sections with known CLTRN expression

  • Recombinant CLTRN-overexpressing cells embedded in paraffin blocks

• Antibody Validation Controls:

  • Peptide competition/preabsorption to verify epitope specificity

  • Dual staining with two different CLTRN antibodies targeting distinct epitopes

• Quantification Standards:

  • Include calibrated reference samples in each experiment

  • Use standardized image acquisition settings across all experimental groups

  • Apply automated quantification algorithms to minimize subjective assessment

• Reproducibility Measures:

  • Process multiple sections from different animals/patients

  • Include technical replicates to assess staining consistency

  • Document detailed protocols including antigen retrieval methods, antibody dilutions, and incubation times

Implementing these controls ensures that observed staining patterns accurately reflect CLTRN distribution rather than technical artifacts or non-specific binding .

How do recent findings on CLTRN's role in diabetic kidney disease inform antibody-based therapeutic approaches?

Recent studies demonstrating CLTRN's critical role in diabetic kidney disease pathogenesis have opened new avenues for antibody-based therapeutics. The finding that CLTRN knockout ameliorates vacuolar formation in proximal tubular cells and reduces albuminuria in diabetic mice suggests that targeted inhibition of CLTRN or its interactions with amino acid transporters could provide therapeutic benefits . Antibody-based approaches might include developing neutralizing antibodies that interfere with CLTRN's chaperone function or blocking antibodies that prevent its interaction with specific transporters like B0AT1 (SLC6A19). These targeted approaches could selectively reduce amino acid influx into proximal tubular cells without affecting other physiological functions. The observed activation of transcription factor EB and consequent improvement in lysosomal function in CLTRN-deficient diabetic mice provides a mechanistic rationale for such therapeutic strategies .

What emerging technologies can enhance the specificity and utility of CLTRN antibodies in research?

Several emerging technologies show promise for enhancing CLTRN antibody research:

Recent advances in deep learning-based antibody design, as described in search result , could be particularly valuable for generating highly specific CLTRN antibodies with optimized developability properties . These computational approaches can generate diverse antibody libraries with desirable biophysical attributes like high expression, monomer content, and thermal stability . Such technologies could accelerate the development of research-grade and potentially therapeutic antibodies targeting CLTRN.

How can quantitative proteomics integrate with CLTRN antibody studies to advance our understanding of amino acid transport dynamics?

Integration of quantitative proteomics with CLTRN antibody studies offers powerful approaches to understanding the complex dynamics of amino acid transport:

• Antibody-based Enrichment: CLTRN antibodies can be used for immunoprecipitation followed by mass spectrometry to identify the complete set of CLTRN-interacting proteins under various physiological and pathological conditions.

• Proximity-dependent Biotinylation: Techniques like BioID or APEX2, where CLTRN is fused to a biotin ligase, can identify proteins in close proximity to CLTRN in living cells, revealing the spatial organization of transport complexes.

• Targeted Proteomics: Selected Reaction Monitoring (SRM) or Parallel Reaction Monitoring (PRM) can quantify CLTRN and its associated transporters with high sensitivity and specificity across multiple samples and conditions.

• Post-translational Modification Analysis: Phosphoproteomics can reveal how signaling pathways like mTOR regulate CLTRN and its transport functions through post-translational modifications.

• Temporal Dynamics: Pulse-chase proteomics combined with CLTRN antibody enrichment can track the synthesis, trafficking, and degradation rates of CLTRN and associated transporters.

These integrated approaches can provide unprecedented insights into how CLTRN orchestrates amino acid transport and how these processes are dysregulated in disease states like diabetic kidney disease .